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Abstract
The renin–angiotensin system (RAS), bone morphogenetic protein (BMP),
and WNT pathways are involved in pathogenesis of diabetic kidney disease
(DKD). This study characterized assays for urinary angiotensinogen (AGT),
gremlin-1, and matrix metalloproteinase 7 (MMP-7), components of the RAS,
BMP, and WNT pathways and examined their excretion in DKD. We mea-
sured urine AGT, gremlin-1, and MMP-7 in individuals with type 1 diabetes
and prevalent DKD (n = 20) or longstanding (n = 61) or new-onset (n = 10)
type 1 diabetes without DKD. These urine proteins were also quantified in
type 2 DKD (n = 11) before and after treatment with candesartan. The uti-
lized immunoassays had comparable inter- and intra-assay and intraindividual
variation to assays used for urine albumin. Median (IQR) urine AGT concen-
trations were 226.0 (82.1, 550.3) and 13.0 (7.8, 20.0) lg/g creatinine in type 1
diabetes with and without DKD, respectively (P < 0.001). Median (IQR) urine
gremlin-1 concentrations were 48.6 (14.2, 254.1) and 3.6 (1.7, 5.5) lg/g,
respectively (P < 0.001). Median (IQR) urine MMP-7 concentrations were 6.0
(3.8, 10.5) and 1.0 (0.4, 2.9) lg/g creatinine, respectively (P < 0.001). Treat-
ment with candesartan was associated with a reduction in median (IQR) urine
AGT/creatinine from 23.5 (1.6, 105.1) to 2.0 (1.4, 13.7) lg/g, which did not
reach statistical significance. Urine gremlin-1 and MMP-7 excretion did not
decrease with candesartan. In conclusion, DKD is characterized by markedly
elevated urine AGT, MMP-7, and gremlin-1. AGT decreased in response to
RAS inhibition, suggesting that this marker reflects therapeutic response. Uri-
nary components of the RAS, BMP, and WNT pathways may identify risk of
DKD and aid development of novel therapeutics.
Introduction
Diabetic kidney disease (DKD) affects 20–40% of individ-
uals with diabetes (Krolewski et al. 1985; Nathan et al.
2009; de Boer et al. 2011a,b). Moreover, its presence and
severity is a strong predictor of long-term mortality
(Groop et al. 2009; Orchard et al. 2010; Afkarian et al.
2013). Development of novel diagnostic and therapeutic
tools is dependent on a deeper understanding of underly-
ing pathophysiologic mechanisms.
Evidence from animal models of DKD supports contri-
bution of three pathways to DKD development: the
renin–angiotensin system (RAS), WNT, and bone mor-
phogenetic protein (BMP) pathways. Activation of the
RAS pathway has been heavily implicated in DKD patho-
physiology and inhibiting it has yielded effective thera-
peutic interventions currently in use (RAS inhibitors).
Angiotensinogen (AGT) is the sole substrate for renin,
which catalyzes the rate-limiting step in the RAS pathway,
eventually yielding angiotensin II, which mediates most of
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the distal effects of the RAS pathway. The BMP pathway
activation counteracts TGF-b signaling while BMP path-
way antagonists, such as gremlin-1, prevent BMP inhibi-
tion of TGF-b signaling (Zeisberg et al. 2003). The WNT
pathway activity, induced by TGF-b signaling, is also
increased in DKD and urinary excretion of MMP-7
(matrix metalloproteinase 7), a target gene highly upregu-
lated by WNT pathway activation, is shown to correlate
with renal WNT pathway activity in animal models of
kidney disease (He et al. 2012).
In this study, we sought to determine if urinary excre-
tion of AGT, gremlin-1, and MMP-7 increases with activa-
tion of the RAS and WNT and inhibition of BMP
pathways in DKD. To do so, we characterized intra- and
interassay and intraindividual variability in the commer-
cially available immunoassays and used these to compare
urinary concentrations of AGT, MMP-7, BMP-7, and
gremlin-1 in people with type 1 diabetes and DKD to those
without kidney disease as well as those with new-onset
type 1 diabetes. Additionally, we examined the change in
urinary concentration of these pathway components in
response to RAS pathway inhibition in type 2 diabetes.
Material and Methods
Study populations
Samples and clinical data from people with type 1 diabetes
were obtained after informed consent either from the Kid-
ney Research Institute Diabetic Kidney Disease Repository
of the University of Washington or the Benaroya Research
Institute Diabetes Translational Research Project. DKD was
defined as either a urine albumin to creatinine ratio (ACR)
≥300 mg/g or an estimated glomerular filtration rate
(GFR) <60 mL/min per 1.73 m2 and ACR ≥30 mg/g. Peo-
ple with longstanding diabetes but no evidence of DKD
had≥30 years of type 1 diabetes, estimatedGFR>90 mL/min
per 1.73 m2, and ACR <300 mg/g. New-onset type 1 diabe-
tes was defined as diagnosis of diabetes ≤12 months prior
to urine sample collection with no hypertension or kidney
disease. The use of these samples and data were approved
by the Institutional Review Boards at the University of
Washington and Benaroya Research Institute.
Samples and clinical data from people with type 2 dia-
betes receiving candesartan were obtained from an open
label dose escalation study of candesartan cilexetil (Saha
et al. 2010). This study included 11 participants with type
2 diabetes and DKD, defined as urine protein excretion
>500 mg/day and 10 participants with type 2 diabetes and
no DKD, defined as urine albumin excretion <30 mg/day.
Exclusion criteria included patients with conditions
associated with elevated TGF-b1 levels, uncontrolled
hypertension, creatinine clearance <30 mL/min, serum
creatinine >3 mg/dL, hemoglobin A1c >10% or major
comorbidities. After a 2-week washout, the participants
with DKD received candesartan doses escalating from 8 to
64 mg/day over a 12-week follow-up period. Use of the
deidentified stored samples and participant data from this
study was considered exempt from review by the Human
Subjects Division of the University of Washington.
Sample collection and storage
For samples from the population with type 1 diabetes, a
spot clean-catch midstream urine sample was obtained
and stored at 4°C immediately after collection until pro-
cessed. To process, urine samples were centrifuged at
4700g for 15 min at 4°C and supernatant was aliquoted
and stored at 80°C until further use. The mean (stan-
dard deviation, SD) time from collection to 80°C stor-
age was 5.7 (2) h. For the samples from the population
with type 2 diabetes, 24-h urine was collected at baseline
and prior to administration of the daily candesartan dose
at the end of each 3-week dose escalation cycle and stored
at 70°C until subsequent use (Saha et al. 2010). For this
study, urine samples from the baseline (no candesartan),
middle (candesartan 16 mg/day), and end of the study
(candesartan 64 mg/day) were used.
Laboratory measurements
Urine samples were thawed at 37°C for 3 min, vortexed,
and either used directly for immunoassays (MMP-7,
AGT) or concentrated fivefold (gremlin-1) using Amicon
10 kDa ultrafiltration units (Millipore, Billerica, MA)
following manufacturer instructions. Urine AGT was
measured using a quantitative solid-phase sandwich
enzyme-Linked immunosorbent assay (ELISA) distributed
by IBL-America (Minneapolis, MN), with a minimum
detection limit of 30 pg/mL and <0.1% cross-reactivity
with human angiotensin I, II, III, or IV, angiotensin (1–
9), or angiotensin (1–7). Urine gremlin-1 was measured
using a quantitative solid-phase sandwich ELISA (Uscnk
Life Sciences, Wuhan, China), with a minimum detection
limit of 60 pg/mL and no significant cross-reactivity with
Cerberus, CTGF, BDNF, or CYR61. Urine MMP-7 was
measured using a quantitative solid-phase sandwich
ELISA (R&D Systems, Minneapolis, MN) with a mini-
mum detection limit of 20 pg/mL and no significant
cross-reactivity with other human MMP or TIMPs.
Assay characterization
Inter- and intra-assay variability was determined as the
coefficient of variation (CV) in technical replicates of the
same samples tested on the same day (intra-assay) or differ-
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ent days (interassay). For intraindividual variation, CVs
were calculated from measurements in spot and 24-h urine
samples, collected from the 11 individuals with type 2 dia-
betes and DKD over a 12-month interval. To determine
protein stability at room temperature, urine samples, col-
lected from six individuals with type 2 diabetes and DKD,
were incubated at room temperature from 1 to 48 h. To
evaluate the effect of frequent freeze–thaw, urine samples
obtained from six individuals with type 2 diabetes and
DKD underwent one, two or five consecutive freeze–thaw
cycles in liquid nitrogen prior to protein quantification.
Statistical analysis
Data are represented as mean (SD) for normally distrib-
uted data and median (interquartile range, IQR) for non-
normal data. Non-normal data were compared using the
Mann–Whitney test. We used multiple linear regression
analysis to test differences in urine proteins, adjusting for
age, gender, race, and diabetes duration. P-values less
than 0.05 were considered statistically significant. Analyses
were performed using the SAS 9.3 statistical software
package (Carey, NC).
Results
Assay and analyte characterization
Gremlin-1 concentrations in unconcentrated urine were
too low to reliably detect. Urine concentration using
ultrafiltration was selected from among four tested con-
centration methods because of a combination of ease,
high yield, and low variability (data not shown). We
characterized the commercially available assays for AGT,
gremlin-1, and MMP-7 for intra- and interassay as well as
intraindividual variation, protein stability after room tem-
perature incubation, and repeated freeze–thaws (Table 1).
The mean intra- and interassay variation was ≤20% for
all proteins, highest for gremlin-1 and lowest for MMP-7.
Intraindividual variation over a 12-month interval for
AGT was comparable to that of albumin and for gremlin-
1 and MMP-7 was lower than that of albumin. Urine
MMP-7 and gremlin-1 had lower variation overtime in
spot samples than 24-h samples. Urine AGT had some-
what higher variation in spot samples than 24 h samples
overtime (Table 1 and Fig. 1). After a 6-h incubation at
room temperature, AGT, gremlin-1, and MMP-7 were all
stable (89%, 93%, and 99% of reference, respectively).
However, after a 24-h incubation, urine AGT and grem-
lin-1 dropped significantly (68% and 86% of reference,
respectively) while MMP-7 was more stable (94% of ref-
erence). Urine AGT and MMP-7 were minimally reduced
after five freeze–thaw cycles, while urine gremlin-1 con-
centration dropped 12% between the second and fifth
freeze–thaw (99% to 87%) (Table 1). Furthermore, addi-
tion of protease inhibitors did not affect urine AGT,
gremlin-1, and MMP-7 concentration (data not shown).
Study populations
Individuals with DKD were younger than those with
longstanding type 1 diabetes but older than those with
new-onset diabetes, as expected (Table 2). They also
included fewer women (30% compared with 56% and
60% in groups with longstanding and new-onset diabetes,
respectively) and fewer Caucasians (85% vs. 97% and
100% in groups with longstanding and new-onset diabe-
tes, respectively). Mean (SD) diabetes duration was 28
(7) years in the group with DKD versus 39 (6) years in
those with longstanding diabetes. Mean hemoglobin A1c
levels were lower in the group with longstanding diabetes
without DKD than the one with DKD (7.4 vs. 8.7).
Hemoglobin A1c levels were not available for the sub-
group with new-onset diabetes. As expected from selec-
tion criteria, mean GFR was much lower in the group
with DKD than the control populations with longstanding
or new-onset type 1 diabetes and no DKD (49, 93, and
120 mL/min per 1.73 m2, respectively). For the same rea-
son, mean ACR exceeded 300 mg/g in people with DKD,
but was normal (<30 mg/g) in both control populations
(Table 2). The population with type 2 diabetes has been
previously described in detail (Saha et al. 2010).
Table 1. Characterization of the immunoassays for angiotensino-
gen, gremlin-1, and MMP-7.
Albumin Angiotensinogen Gremlin-1 MMP-7
Intra-assay CV (%) ND 8.2 (5.4) 13.3 (4.4) 5.4 (5.2)
Interassay CV (%) ND 14 (9) 20 (14) 9 (7)
Intraindividual CV over 12 months (%)
24 h AER 64 42 37 51
24 h ACR 56 57 21 28
Spot ACR 46 64 15 29
Stability at room temperature (% of reference)
1 h incubation
(reference)
ND 100 100 100
6 h incubation 89 93 99
24 h incubation 68 86 94
48 h incubation 63 51 88
Stability to freeze–thaw (% of reference)
1 freeze–thaw
(reference)
ND 100 100 100
2 freeze–thaws 95 99 98
5 freeze–thaws 92 87 94
Values for intra- and interassay CVs are represented as mean (SD).
ND, not determined.
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Urinary concentration of AGT, MMP-7, and
gremlin-1 in type 1 diabetes
Urine concentration of AGT, MMP-7, and gremlin-1
showed statistically significant moderate correlations with
albuminuria in the combined cohort (R2 = 0.54, 0.41,
and 0.20 for AGT, MMP-7, and gremlin-1, respectively;
P < 0.001) (Table 3). Creatinine-adjusted urine AGT was
17-fold higher with DKD than without DKD and 26-fold
higher than urine AGT concentration at the onset of type
Figure 1. Intraindividual variability in urine AGT, gremlin, and MMP-7. Distribution of coefficients of variation (CV) for each analyte measured
in urine samples collected at 0, 3, and 12 months. An/Cr, analyte to creatinine ratio in spot and 24-h urine collections; AnER, analyte excretion
rate. The dashed lines represent the intraindividual CVs for urine albumin excretion in the same samples.
Table 2. Characteristics of the participants with type 1 diabetes.
Longstanding diabetes with no
kidney disease1 Diabetic kidney disease1
New-onset diabetes with
no kidney disease1
P-value
Mean (SD) or
number (proportion, %)
Mean (SD) or
number (proportion, %)
Mean (SD) or
number (proportion, %)
N 61 20 10
Age (years) 50 (9) 43 (9) 30 (14) <0.001
Female N (%) 34 (56) 6 (30) 6 (60) 0.11
Caucasian N (%) 59 (97) 17 (85) 10 (100) 0.31
DM duration (Years) 39 (6) 28 (7) 1 (0) <0.001
Hemoglobin A1c (%) 7.4 (0.8) 8.7 (1.2) NA <0.001
GFR (mL/min per 1.73 m2) 93 (12) 49 (24) 120 (24) <0.001
ACR (mg/g) 10 (11) 680 (588) 7 (4) <0.001
RAAS inhibitor use (%) 52 90 0 <0.001
1DKD was defined as a urine albumin to creatinine ratio (ACR) ≥300 mg/g or estimated GFR <60 mL/min per 1.73 m2 and ACR ≥30 mg/g.
Longstanding diabetes with no kidney disease were individuals with ≥30 years of type 1 diabetes, estimated GFR >90 mL/min per 1.73 m2,
and ACR <300 mg/g. NA, hemoglobin A1c levels were not available for the subgroup with new-onset diabetes.
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Page 4
ª 2014 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.
RAS, BMP, and WNT Pathways in DKD M. Afkarian et al.
1 diabetes (Fig. 2). Median urine AGT/Cr (AGT concen-
tration normalized to urine creatinine) in cases (226.0 ng/
mg) was significantly different from those in controls
(13.0 ng/mg) and participants with new-onset type 1 dia-
betes (8.7 ng/mg). These relations were unaffected by
adjustment for age, race, gender, diabetes duration, and
RAS inhibitor use, as well as correction for multiple test-
ing using the Bonferroni method (P < 0.001). The differ-
ence in median AGT/Cr levels between people with DKD
versus longstanding diabetes without DKD remained sig-
nificant after additional adjustment for hemoglobin A1c
(P < 0.001).
Creatinine-adjusted urine MMP7 concentration was
sixfold higher in people with type 1 diabetes and DKD
than those with no DKD and 6.7-fold higher than in
newly diagnosed diabetes. Median urine MMP-7/Cr
(MMP-7 concentration normalized to urine creatinine) in
cases (6.0 ng/mg) was significantly different from those in
controls (1.0 ng/mg) and participants with new-onset
type 1 diabetes (0.9 ng/mg). These relations were unaf-
fected by adjustment for age, race, gender, diabetes dura-
tion, and RAS inhibitor use, as well as correction for
multiple testing using the Bonferroni method (P < 0.001)
(Fig. 2). The difference in median MMP-7/Cr levels
between people with DKD versus longstanding diabetes
without DKD remained significant after additional adjust-
ment for hemoglobin A1c (P < 0.001).
Creatinine-adjusted urine gremlin-1 concentration was
13-fold higher in people with type 1 diabetes and DKD
than those with no DKD and 27-times higher than urine
gremlin-1 concentration at the onset of type 1 diabetes.
Median urine gremlin-1/Cr (gremlin-1 concentration nor-
malized to urine creatinine) in cases (48.6 ng/mg) was
significantly different from those in controls (3.6 ng/mg)
and participants with new-onset type 1 diabetes (1.8 ng/
mg) (Fig. 2). These relations were unaffected by adjust-
ment for age, race, gender, diabetes duration, and RAS
inhibitor use, as well as correction for multiple testing
using the Bonferroni method (P < 0.001). The difference
in median gremlin-1/Cr levels between people with DKD
versus longstanding diabetes without DKD remained
significant after additional adjustment for hemoglobin
A1c (P < 0.001). USAG1, another BMP pathway antago-
nist, was present in urine in concentrations 1000-fold
lower than gremlin-1 and was not further pursued. Urine
BMP-7 concentration was not detectable in samples con-
centrated up to 200-fold and as such was estimated to be
less than 0.5 pg/mL.
Effect of RAS inhibition on urine
concentration of AGT, MMP-7, and gremlin-1
in type 2 diabetes
Median (IQR) of urine AGT/Cr concentration was 23.5
(1.6, 105.1) at study baseline (before candesartan) and 2.0
(1.4, 13.7) after 4 months of treatment with candesartan
(candesartan 64 mg/day at study end). Median (IQR)
Table 3. Correlations (R2 linear regression) between urinary excre-
tion of albumin, AGT, gremlin-1, and MMP-7.
ACR MMP7 AGT Gremlin-1
ACR 1.00 0.41 0.54 0.20
MMP7 1.00 0.25 0.07
AGT 1.00 0.09
Gremlin-1 1.00
All correlations are statistically significant (P < 0.001).
Figure 2. Urine AGT, MMP-7, and gremlin-1 in type 1 diabetes with or without DKD. Urine AGT/Cr, MMP-7/Cr, and gremlin-1/Cr in random
urine samples from people with new-onset T1D, longstanding T1D with no DKD, and people with T1D and DKD. P-values are from
Mann–Whitney comparison between the data-points. *P < 0.001.
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urine MMP-7 were 2.3 (1.1, 3.0) and 3.5 (1.7, 8.7) at
study baseline and end. Median (IQR) urine gremlin-1
were 2.5 (0.7, 4.2) and 3.0 (2.3, 7.8) at study baseline and
end (Fig. 3). Of the 11 participants with DKD, six had
lower albuminuria at the end of the study (“responders”),
while five had equal or higher albumin concentration at
the end of the study (“nonresponders”). Median (IQR)
urine AGT/Cr tended to be higher in responders than
nonresponders (67.4 (25.6, 118.8) and 1.3 (1.1, 2.2),
respectively). Median (IQR) urine gremlin-1 was 3.6 (2.7,
4.3) in responders versus 0.5 (0.5, 1.5) in nonresponders.
Median (IQR) urine MMP-7 concentration was 3.3 (2.7,
4.0) in nonresponders versus 1.8 (0.9, 2.3) in responders.
These differences were not statistically significant, likely
due to small sample sizes.
Discussion
The primary finding of this study is that urine AGT,
MMP-7, and gremlin-1 concentration are markedly ele-
vated in people with type 1 diabetes and DKD, compared
with those with recently diagnosed type 1 diabetes or
those with longstanding type 1 diabetes without DKD.
We also found that in type 2 diabetes, treatment with an
angiotensin receptor antagonist tended to reduce urine
AGT concentration, but not urine MMP-7 or gremlin-1.
Urine AGT, MMP-7, and gremlin-1 were quantified using
optimized commercially available assays, which had
acceptable inter- and intra-assay variation, comparable or
better intraindividual variability than that of albumin,
and stable protein quantification after up to 6 h at room
temperature or two freeze–thaws.
Data from animal models and some human studies sup-
port involvement of the RAS, BMP, and WNT pathways
in DKD pathophysiology. Kidney AGT expression is
increased in several DKD animal models, where AGT is
induced by angiotensin II and promotes progression of
kidney disease (Kobori et al. 2002, 2003; Singh et al. 2005;
Liu et al. 2007; Ohashi et al. 2010). AGT expression is also
increased in human biopsies with DKD (Lai et al. 1998)
and urine samples from people with type 2 diabetes and
kidney disease (Kobori et al. 2008; Kim et al. 2012). Fur-
thermore, urinary AGT concentration strongly correlates
with renal angiotensin II and RAS pathway activity (Ya-
mamoto et al. 2007; Nishiyama et al. 2011), suggesting
that AGT may be both a biologic mediator and a read-out
of the RAS activity. Urine AGT is associated with GFR loss
over 2 years of follow-up in type 2 diabetes, even after
adjustment for baseline proteinuria and GFR (Yamamoto
et al. 2007). Compared with individuals without diabetes,
urine AGT concentration is also increased in people with
type 1 diabetes and normal urine albumin excretion (Saito
et al. 2009). However, urine AGT concentration has not
been reported in type 1 diabetes with kidney disease.
Figure 3. Urine AGT, gremlin-1, and MMP-7 before and after treatment with candesartan in type 2 diabetes. Urine AGT concentration is
lower after 4.2 (1.7) months of candesartan. Urine MMP-7 and gremlin-1 are not altered by candesartan. These differences were not
statistically significant, likely due to small sample sizes. The 1-month visit occurred 1.1 (1.3) months after baseline visit; the 4-month visit
occurred 4.2 (1.7) months after the baseline visit. Proteins were measured in 24 h urine collections.
2014 | Vol. 2 | Iss. 5 | e12010
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The central mediator of the WNT pathway, b-catenin,
is activated (translocated to the nuclei) in kidneys of sev-
eral DKD animal models (Kato et al. 2011; Rooney et al.
2011; Zhou et al. 2012) and inhibition of the WNT path-
way ameliorates podocyte injury, albuminuria, and fibro-
sis (Dai et al. 2009; He et al. 2009, 2011; Hao et al.
2011), though one report suggests a more complex pic-
ture with some WNT pathway activity necessary for
podocyte survival (Kato et al. 2011). Increased expression
of WNT pathway components has also been noted in
human DKD biopsies (Cohen et al. 2008; Dai et al. 2009;
Kato et al. 2011; He et al. 2012), with MMP-7 being the
most highly induced WNT target in mRNA arrays of dia-
betic kidney tissue (Cohen et al. 2008). While urine
MMP-7 correlates with WNT pathway activity in animal
models (He et al. 2012), urine MMP-7 concentration has
not been studied in humans.
In animal models of DKD, kidney expression of BMP-7
is reduced and gremlin-1 is increased long before the
onset of overt DKD (McMahon et al. 2000; Wang et al.
2001; Yeh et al. 2009). Inhibition of the BMP pathway by
reducing BMP-7 expression leads to mesangial matrix
expansion (Miyazaki et al. 2006), while activation of the
pathway by reducing gremlin-1 or overexpressing BMP-7
expression ameliorates DKD manifestations (Wang et al.
2003, 2006; Sugimoto et al. 2007; Roxburgh et al. 2009;
Zhang et al. 2010). Human biopsies of DKD also demon-
strate elevated gremlin-1 and reduced BMP-7 expression
(Dolan et al. 2005; De Petris et al. 2007; Walsh et al.
2008; Turk et al. 2009). However, urine concentration of
BMP pathway components has not been described in
human kidney disease.
We find that urine concentration of AGT, MMP-7, and
gremlin-1 is low at the onset of type 1 diabetes and remains
low in people who have intact kidney function after 30 or
more years of type 1 diabetes. However, the concentration
of each protein is markedly elevated in people with type 1
diabetes who develop DKD. Examining urinary concentra-
tion of these proteins in people with intact kidney function
(GFR >90 mL/min per 1.73 m2 and no macroalbuminuria)
after 30 or more years of diabetes avoids the potential mis-
classification of individuals with cross-sectional normoal-
buminuria as controls, since this latter group may harbor
individuals with early or nonalbuminuric DKD. Further-
more, the finding of low urinary concentration of AGT,
gremlin-1, and MMP-7 in new-onset type 1 diabetes estab-
lishes a starting point for the trajectory of concentration of
these proteins in the time course of DKD. This suggests that
concentration of these proteins rises in urine of people with
type 1 diabetes who go on to develop DKD, but not in those
who do not develop DKD, possibly reflecting the known
derangement of intrarenal RAS, WNT, and BMP pathways
with progression of DKD. This raises the possibility that the
increase in urinary concentration of these proteins may
occur early enough in DKD course to be of value for detec-
tion of earlier stages of DKD. The cross-sectional data pre-
sented here support examining association of urinary
concentration of these proteins at earlier time points with
subsequent development of DKD in a longitudinal study.
We also find that treatment with an inhibitor of the
RAS pathway shows a trend toward reducing urine AGT
to creatinine concentration, as reported previously
(Yamamoto et al. 2007; Ogawa et al. 2009; Nishiyama
et al. 2011), but not urine MMP-7 or gremlin-1. The het-
erogeneity in response to RAAS inhibitors in terms of
ACR reduction is well-documented (Hellemons et al.
2011; Holtkamp et al. 2011). In our cohort of 11 people,
six had lower albuminuria at the end of the study
(“responders”), while five had no reduction in albumin
concentration at the end of the study (“nonresponders”).
We found that the response to RAS inhibition in terms of
reduction in albuminuria was observed in people with
higher baseline urine AGT, as was also noted in prior
studies (Ogawa et al. 2009; Jang et al. 2012). These find-
ings suggest two interesting possibilities. First, if urine
concentrations of these proteins are a reflection of intra-
renal activities of the corresponding pathways, the WNT
and BMP pathways appear unaffected with RAS inhibi-
tion and could present potential therapeutic targets in
addition to the RAS pathway. A peptide agonist of the
BMP pathway is currently being tested and has shown
promise in reversal of kidney injury and fibrosis in animal
models (Sugimoto et al. 2012). Furthermore, elevated uri-
nary concentration of these proteins may identify patients
in whom dysregulation of the corresponding pathway
contributes to DKD, allowing optimal targeting of the
respective therapies to appropriate subsets of patients.
Strengths of this study include a first-pass evaluation, as
potential biomarkers, of novel urinary proteins represent-
ing promising candidate pathways, quantification of these
urine proteins using a well characterized process from
urine collection to assay, and use of a carefully ascertained
extreme case–control population. The study has limita-
tions. As DKD was not confirmed by a kidney biopsy,
inclusion of other causes of kidney disease among our cases
is possible. Other limitations are the cross-sectional study
design, small sample size, and lack of parallel quantifica-
tion of protein concentrations in serum or kidney tissue.
In conclusion, using carefully characterized assays, we
find that in people with type 1 diabetes who have DKD,
urine concentration of AGT, MMP-7, and gremlin-1 are
markedly higher than in individuals with new onset of
diabetes or those with longstanding diabetes without
DKD. We also find a decrease in urine AGT, but not
MMP-7 or gremlin-1, in response to RAS inhibition in
people with type 2 diabetes and DKD, potentially reflect-
ª 2014 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.
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ing therapeutic response. Urinary components of the
RAS, BMP, and WNT pathways may identify risk of DKD
as well as aid in development of novel therapies.
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